LONG R3IGF-I is an analogue of IGF-I engineered for biopharmaceutical protein production in mammalian cells, supporting growth and survival in serum-free media at concentrations at least 200-fold lower than insulin.
preclinical — animal, cell or mechanistic work — not yet about people
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'IGF-1 LR3' with aliases Long R3 IGF-1, LongR3 IGF-I, LR3-IGF-1, Long Arg3 IGF-1 · 2026-09-27 04:00 · somebody
kind set kind set to peptide: palette r1 · 2026-09-27 04:00 · somebody
identity withheld identity not published: PubChem gave no record that proves it is this substance · 2026-09-27 04:00 · somebody
fact added summary: LONG R3IGF-I is an analogue of IGF-I engineered for biopharmaceutical protein production in mammalian cells, supporting · 2026-09-27 04:00 · somebody
fact added mechanism: It has markedly reduced binding to IGF-binding proteins; in rats it circulated mostly as free peptide and was cleared fr · 2026-09-27 04:00 · somebody
citation added pmid 17172665 cited as preclinical: LONG R3IGF-I as a potent alternative to insulin in serum-free cell culture · 2026-09-27 04:00 · somebody
citation added pmid 7693845 cited as preclinical: Plasma clearance and tissue distribution of LR3IGF-I in rats · 2026-09-27 04:00 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.